MSD And CKD In Multi-Product Korea Partnership To Boost Sales
This article was originally published in PharmAsia News
Executive Summary
Chong Kun Dang Pharmaceutical has tied up with MSD Korea to beef up its diabetes and hyperlipidemia portfolios, in a move that could also help the US firm benefit from the South Korean pharma's leading position in the domestic cardiovascular market.